Venous thromboembolism (VTE) is highly prevalent in people undergoing treatment for cancer. Serious consequences for cancer patients facing VTE include the need for hospitalization, long-term anticoagulation, and death. Recently, large clinical trials have addressed thromboprophylaxis in the outpatient setting, with the potential benefit of reducing morbidity and mortality; however, many studies also show considerable variation in underlying risk.
In this webinar, Dr. Khorana will discuss the current risk assessment tools used to identify patients at high risk for cancer-associated VTE. He will also discuss emerging data on biomarkers, review the latest data and guidelines on prevention of VTE in cancer, and present best approaches to treatment of VTE in patients with active malignancy.
- Identify two approaches to identifying risk of cancer-associated venous thromboembolism.
- Describe one approach to prophylaxis for high-risk patients.
- Describe two treatment options for cancer-associated venous thromboembolism.
This webinar is free and open to public health professionals, clinicians, and researchers who desire more information about thrombosis. Advance registration is required, and the number of attendees is limited.